undamentalytics Newsletter
Sign in

Axogen, Inc. revenue

Axogen, Inc.'s revenue was $225m in fiscal 2025, up 20.2% on the year before. Since fiscal 2010 ($3.0m) it has grown at a compound 33.3% a year. Over the last twelve months it was $267m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue358111727416084107112127139159187225267
Growth on the year before—+61.4%+58.6%+42.3%+53.6%+62.5%+50.4%+47.0%+38.9%+27.1%+5.2%+13.4%+8.8%+14.7%+17.8%+20.2%—
Gross profit226913223551718991104109122142167198
Gross margin54.1%50.0%74.5%77.7%79.5%82.3%84.3%84.6%84.6%83.7%80.8%82.0%78.5%76.6%75.8%74.3%74.2%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
United States $222M 98.8% ▲ 20.7%
Outside the US $2.8M 1.2% ▼ 10.2%

From Axogen, Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Axogen, Inc. $267m 24.3% 20.6%
Orthopediatrics Corp $264m 16.1% 23.0%
Lemaitre Vascular Inc $262m 11.8% 14.0%
Cerus Corp $254m 74.6% 89.8%
Establishment Labs Holdings Inc. $246m 38.6% 11.5%
Skinhealth Systems Inc. $290m -6.5% -9.5%

Compare with peers

Head to head: AXGN vs KIDSAXGN vs LMATAXGN vs CERSAXGN vs SKIN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Axogen, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Axogen, Inc.